CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 37 enrolled
Drug / intervention
BIBF 1120drug
Likely dose
BIBF 1120 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01380782
NCT01380782Phase 2Completed
CompareCT.gov

Phase II Trial of Triple Receptor Tyrosine Kinase Receptor Inhibitor BIBF 1120 in Recurrent High-Grade Gliomas

Patrick Y. Wen, MD·interventional·Posted Jun 27, 2011·Updated Aug 18, 2014

In Brief

A Phase 2 clinical trial evaluating BIBF 1120 for Glioblastoma and 4 related conditions. Completed, enrolled 37 participants across 4 sites.

Detailed Summary

BIBF 1120 is a newly discovered compound that may stop cancer cells from growing abnormally. This drug is currently being used in treatment for other cancers in research studies and information from those other research studies suggests that this agent, BIBF 1120, may help to stop recurrent malignant glioma cells from multiplying and it may also prevent the growth of new blood vessels at the site of the tumor. In this research study, the investigators are looking to see how well BIBF 1120 works in patients with recurrent malignant gliomas.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlioblastoma, Gliosarcoma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Anaplastic Oligoastrocytoma
CountriesUnited States
CollaboratorsBoehringer Ingelheim, Wake Forest University Health Sciences, University of Virginia, Massachusetts General Hospital, The Cleveland Clinic

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJun 27, 2011
Enrollment StartMay 1, 2012
Primary CompletionJul 1, 2013
Study CompletionJul 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 15.0 years ago

Interventions

BIBF 1120drug

200 mg BID oral for 28 day cycle